1. Home
  2. DETX vs BLRX Comparison

DETX vs BLRX Comparison

Compare DETX & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Defense Holdings Ltd. Common Shares

DETX

Liberty Defense Holdings Ltd. Common Shares

N/A

Current Price

$2.14

Market Cap

14.8M

ML Signal

N/A

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

HOLD

Current Price

$2.36

Market Cap

12.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DETX
BLRX
Founded
N/A
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.8M
12.0M
IPO Year
2022
2010

Fundamental Metrics

Financial Performance
Metric
DETX
BLRX
Price
$2.14
$2.36
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $19.00
AVG Volume (30 Days)
★ 33.6K
15.2K
Earning Date
N/A
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.91
$2.15
52 Week High
$4.25
$4.56

Technical Indicators

Market Signals
Indicator
DETX
BLRX
Relative Strength Index (RSI) 36.75 40.74
Support Level $1.97 $2.18
Resistance Level $2.43 $2.51
Average True Range (ATR) 0.24 0.12
MACD 0.02 0.00
Stochastic Oscillator 38.78 14.81

Price Performance

Historical Comparison
DETX
BLRX

About DETX Liberty Defense Holdings Ltd. Common Shares

Liberty Defense Holdings Ltd is engaged in the development and commercialization of security detection technologies such as airports, stadiums, schools, and more. The company's Hexwave product utilizes millimeter wave technology and Advanced 3D imaging to detect concealed threats. In addition to HEXWAVE, the company has licensed High-Definition Advanced Imaging Technology (HD-AIT) for body and shoe scanning. The Company operates through three distinct segments: Corporate, HEXWAVE, and Contract. The company generates the majority of its revenue from the Contract segment. Geographically, the company generates the majority of its revenue from the United States.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: